share_log

Virpax Pharmaceuticals | DEFA14A: Others

SEC ·  Jul 9 04:38

Summary by Futu AI

Virpax Pharmaceuticals, Inc. has issued a supplement to its definitive proxy statement, detailing significant changes ahead of its 2024 Annual Meeting of Stockholders scheduled for July 29, 2024. The supplement, dated July 5, 2024, follows the company's entry into a Securities Purchase Agreement with an institutional investor, resulting in a $2.5 million financing deal. This transaction prompted a reorganization of the company's Board of Directors, with the resignation of five directors and the appointment of four new ones, including Judy Su, Jatinder Dhaliwal, Katharyn Field, and Gary Herman. Dr. Jeffrey Gudin's resignation as a Class III director led to Gary Herman's appointment in his stead, with Herman now standing for reelection at the upcoming Annual Meeting. The Board has been restructured into...Show More
Virpax Pharmaceuticals, Inc. has issued a supplement to its definitive proxy statement, detailing significant changes ahead of its 2024 Annual Meeting of Stockholders scheduled for July 29, 2024. The supplement, dated July 5, 2024, follows the company's entry into a Securities Purchase Agreement with an institutional investor, resulting in a $2.5 million financing deal. This transaction prompted a reorganization of the company's Board of Directors, with the resignation of five directors and the appointment of four new ones, including Judy Su, Jatinder Dhaliwal, Katharyn Field, and Gary Herman. Dr. Jeffrey Gudin's resignation as a Class III director led to Gary Herman's appointment in his stead, with Herman now standing for reelection at the upcoming Annual Meeting. The Board has been restructured into three classes, with the current composition being seven directors. The company has also updated its proxy card to reflect the nominee changes and advises stockholders who have already voted and do not wish to change their vote that no further action is required. The proxy materials, including the amended notice, proxy statement, supplement, updated proxy card, and the 2023 Annual Report, are available at www.proxyvote.com.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.